IP Library › Granted Patent US 9,526,755
Granted Patent B2
US 9,526,755 · App. 14/726,221 · Granted Dec 27, 2016

Jucara and Açai fruit-based compositions

Inventors: Kenneth A. Murdock (Springville, UT); Alexander G. Schauss (Tacoma, WA)
A61K36/889A23L1/2121A23L1/3002A61K9/0053A61K2236/51
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,526,755
App. No.
14/726,221
Granted
Dec 27, 2016
Kind
B2
Abstract

The present invention relates to stable, palatable, freeze-dried, fruit-based compositions. Specifically, the inventions relates to compositions of Açai fruit and Jucara fruit with high antioxidant capability and cyclooxygenase-inhibitory activity, and their uses. The invention further provides for methods of making stable, palatable, freeze-dried, fruit-based compositions from Açai fruit and Jucara fruit.

Claims (13)

1. An oral composition comprising freeze-dried açai fruit pulp and a pharmaceutically acceptable carrier, wherein the freeze-dried açai fruit pulp prior to being combined with the pharmaceutically acceptable carrier was frozen at a temperature of −5° C. or less, and has an anthocyanin concentration greater than 0.5 milligram per gram total weight and an ORAC FL value greater than about 350 micromole TE per gram total weight; and wherein the oral composition is contained in a capsule, tablet or caplet.

2. The oral composition of claim 1 , wherein the pharmaceutically acceptable carrier comprises one or more of a binder, an excipient, a lubricant, a flavoring compound and a sweetening agent.

3. The oral composition of claim 1 , wherein the pharmaceutically acceptable carrier comprises a binder, an excipient and a sweetening agent.

4. The oral composition of claim 1 , wherein the binder is selected from the group consisting of cellulose and gum, and the excipient is selected from the group consisting of starch and lactose.

5. The oral composition of claim 1 , wherein the pharmaceutically acceptable carrier comprises: cellulose, gum, starch, and a sweetening agent.

6. The oral composition of claim 1 , wherein the pharmaceutically acceptable carrier comprises ascorbic acid.

7. An oral composition comprising freeze-dried juçara fruit pulp and a pharmaceutically acceptable carrier, wherein the freeze-dried juçara fruit pulp prior to being combined with the pharmaceutically acceptable carrier was frozen at a temperature of −5° C. or less, and has an anthocyanin concentration greater than 0.5 milligram per gram total weight and an ORAC FL value greater than about 350 micromole TE per gram total weight; and wherein the oral composition is contained in a capsule, tablet or caplet.

8. The oral composition of claim 7 , wherein the pharmaceutically acceptable carrier comprises one or more of a binder, an excipient, a lubricant, a flavoring compound and a sweetening agent.

9. The oral composition of claim 7 , wherein the pharmaceutically acceptable carrier comprises a binder, an excipient and a sweetening agent.

10. The oral composition of claim 7 , wherein the binder is selected from the group consisting of cellulose and gum, and the excipient is selected from the group consisting of starch and lactose.

11. The oral composition of claim 7 , wherein the pharmaceutically acceptable carrier comprises: cellulose, gum, starch, and a sweetening agent.

12. The oral composition of claim 7 , wherein the pharmaceutically acceptable carrier comprises ascorbic acid.

13. An oral composition comprising a mixture of freeze-dried juçara fruit pulp and freeze-dried açai fruit pulp and a pharmaceutically acceptable carrier, wherein the mixture prior to being combined with the pharmaceutically acceptable carrier was frozen at a temperature of −5° C. or less, and has an anthocyanin concentration greater than 0.5 milligram per gram total weight and an ORAC FL value greater than about 350 micromole TE per gram total weight; and wherein the oral composition is contained in a capsule, tablet or caplet.

Continuity (6)
Continuation 13442858 · Apr 10, 2012
Continuation 12760395 · Apr 14, 2010
Continuation 12498269 · Jul 6, 2009
Continuation 10550502
Provisional Application 60456882 · Mar 21, 2003
Related Publication 20150258163A1 · Sep 17, 2015